Staphylococcus equorum and Staphylococcus succinus isolated from human clinical specimens.
A polyphasic identification approach was applied to a group of 11 novobiocin-resistant staphylococci isolated from human clinical materials. Phenotypic characteristics obtained by both commercial and conventional tests assigned eight strains as Staphylococcus xylosus and three strains as ambiguous S. xylosus/Staphylococcus equorum. In contrast to biotyping, ribotyping with EcoRI and HindIII restriction endonucleases and whole-cell protein fingerprinting assigned six analysed strains as S. equorum, and five strains as Staphylococcus succinus. Confirmation of the identification was done by partial 16S rRNA gene sequencing and S. equorum isolates were verified by a PCR assay targeting the sodA gene. From the data it has been implied that ribotyping and whole-cell protein analysis can be used to differentiate between the biochemically almost indistinguishable species S. xylosus, S. equorum and S. succinus. The present study confirms what is believed to be the first occurrence of S. equorum in a relevant human clinical material in the Czech Republic and describes what is believed to be the first-ever isolation of S. succinus from human clinical material.
Czech Collection of Microorganisms, Faculty of Science, Masaryk University, Tvrdého 14, 602 00, Brno, Czech Republic.
Dana
D
Nováková
Czech Collection of Microorganisms, Faculty of Science, Masaryk University, Tvrdého 14, 602 00, Brno, Czech Republic.
Ivo
I
Sedláček
Department of Genetics and Molecular Biology, Faculty of Science, Masaryk University, Kotlářská 2, 611 37, Brno, Czech Republic.
Roman
R
Pantůček
Czech Collection of Microorganisms, Faculty of Science, Masaryk University, Tvrdého 14, 602 00, Brno, Czech Republic.
Vlastimil
V
Štětina
Czech Collection of Microorganisms, Faculty of Science, Masaryk University, Tvrdého 14, 602 00, Brno, Czech Republic.
Pavel
P
Švec
Reference Laboratory for Staphylococci, National Institute of Public Health, Šrobárova 48, 100 42, Praha 10, Czech Republic.
Petr
P
Petráš
D000293:Adolescent; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000032:analysis / Q000235:genetics; D015373:Bacterial Typing Techniques; D002648:Child; D016000:Cluster Analysis; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009675:Novobiocin / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D020543:Proteome / Q000032:analysis; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D021521:Ribotyping; D017422:Sequence Analysis, DNA; D013203:Staphylococcal Infections / Q000382:microbiology*; D013210:Staphylococcus / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification* / Q000502:physiology; D013482:Superoxide Dismutase / Q000235:genetics
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D020543:Proteome; D012336:RNA, Ribosomal, 16S; D009675:Novobiocin; C095500:SodA protein, Bacteria; D013482:Superoxide Dismutase